Movement Alert｜Eli Lilly Rises 3.14% in Regular Trading, Pharma Sector Rebounds as Medicare GLP-1 Bridge Program Officially Launches

Market Focus07-02 22:36

On July 2, Eli Lilly rose 3.14% in regular trading, trading at approximately $1,230 per share, with turnover of $6.99 billion. The stock rebounded sharply following a 3% decline on June 30, when markets initially sold off on news that obesity drugs were being included in federal Medicare coverage for the first time.

The rebound appears driven by the market reassessing the long-term positive impact of the Medicare GLP-1 Bridge Program, which officially launched on July 1. Under the program, eligible Medicare Part D beneficiaries can access Lilly's weight management medicines Foundayo and Zepbound for just $50 per month through December 31, 2027. Lilly estimates approximately 15 to 20 million Medicare beneficiaries may meet clinical criteria to use these medications, representing a substantial incremental market opportunity for the company's GLP-1 franchise.

The broader pharmaceutical sector rallied in tandem, with AstraZeneca gaining 5.49%, Novo Nordisk rising 4.07%, Pfizer up 2.37%, Merck adding 2.26%, and Johnson & Johnson climbing 2.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148873770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148873770","market":"us","top_or_hot":-1,"title":"Movement Alert｜Eli Lilly Rises 3.14% in Regular Trading, Pharma Sector Rebounds as Medicare GLP-1 Bridge Program Officially Launches","media":"Market Focus","content":"<p><p>On July 2, Eli Lilly rose 3.14% in regular trading, trading at approximately $1,230 per share, with turnover of $6.99 billion. The stock rebounded sharply following a 3% decline on June 30, when markets initially sold off on news that obesity drugs were being included in federal Medicare coverage for the first time.</p><p>The rebound appears driven by the market reassessing the long-term positive impact of the Medicare GLP-1 Bridge Program, which officially launched on July 1. Under the program, eligible Medicare Part D beneficiaries can access Lilly's weight management medicines Foundayo and Zepbound for just $50 per month through December 31, 2027. Lilly estimates approximately 15 to 20 million Medicare beneficiaries may meet clinical criteria to use these medications, representing a substantial incremental market opportunity for the company's GLP-1 franchise.</p><p>The broader pharmaceutical sector rallied in tandem, with AstraZeneca gaining 5.49%, Novo Nordisk rising 4.07%, Pfizer up 2.37%, Merck adding 2.26%, and Johnson & Johnson climbing 2.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Eli Lilly Rises 3.14% in Regular Trading, Pharma Sector Rebounds as Medicare GLP-1 Bridge Program Officially Launches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Eli Lilly Rises 3.14% in Regular Trading, Pharma Sector Rebounds as Medicare GLP-1 Bridge Program Officially Launches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Eli Lilly rose 3.14% in regular trading, trading at approximately $1,230 per share, with turnover of $6.99 billion. The stock rebounded sharply following a 3% decline on June 30, when markets initially sold off on news that obesity drugs were being included in federal Medicare coverage for the first time.</p><p>The rebound appears driven by the market reassessing the long-term positive impact of the Medicare GLP-1 Bridge Program, which officially launched on July 1. Under the program, eligible Medicare Part D beneficiaries can access Lilly's weight management medicines Foundayo and Zepbound for just $50 per month through December 31, 2027. Lilly estimates approximately 15 to 20 million Medicare beneficiaries may meet clinical criteria to use these medications, representing a substantial incremental market opportunity for the company's GLP-1 franchise.</p><p>The broader pharmaceutical sector rallied in tandem, with AstraZeneca gaining 5.49%, Novo Nordisk rising 4.07%, Pfizer up 2.37%, Merck adding 2.26%, and Johnson & Johnson climbing 2.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1148873770","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148873770","pubTimestamp":1783003011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Eli Lilly rose 3.14% in regular trading, trading at approximately $1,230 per share, with turnover of $6.99 billion. The stock rebounded sharply following a 3% decline on June 30, when...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"动向提示|礼来常规交易涨3.14%医药板块反弹因Medicare GLP-1桥梁计划正式启动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"On July 2, Eli Lilly rose 3.14% in regular trading, trading at approximately $1,230 per share, with turnover of $6.99 billion. The stock rebounded sharply following a 3% decline on June 30, when markets initially sold off on news that obesity drugs were being included in federal Medicare coverage for the first time.The rebound appears driven by the market reassessing the long-term positive impact of the Medicare GLP-1 Bridge Program, which officially launched on July 1. Under the program, eligible Medicare Part D beneficiaries can access Lilly's weight management medicines Foundayo and Zepbound for just $50 per month through December 31, 2027. Lilly estimates approximately 15 to 20 million Medicare beneficiaries may meet clinical criteria to use these medications, representing a substantial incremental market opportunity for the company's GLP-1 franchise.The broader pharmaceutical sector rallied in tandem, with AstraZeneca gaining 5.49%, Novo Nordisk rising 4.07%, Pfizer up 2.37%, Merck adding 2.26%, and Johnson & Johnson climbing 2.05%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148873770","isCrawlerRequest":true}